|
| Alkem has reinforced its focus on R & D and has substantially scaled up on its investments to build its capabilities in all the areas of generic research as a short to medium term strategy. Generic drug development encompasses both small and large molecules. Alkem strongly believes that there are attractive opportunities in the highly competitive global generic space, not only in vanilla generics but also in value added and difficult to develop complex generics. The business focus is backed with the building up of captive manufacturing operations and of complying with the regulatory standards of the advanced markets. Focus on the generics business strategy will provide the company with a sustainable model to move up the value chain. Today, the company includes a group of more than 200 R & D scientists, with performance driven credentials, in all the disciplines of generic drug development, as their asset to steer forward in its current aspirations. |
|
| Alkem's generic drug development meets the speed and quality attributes, as all the elements of research have been conducted within the same campus, situated at Taloja, Navi Mumbai. Alkem can proudly claim its own 40 bed bioavailability and bioequivalence testing facilities that could meet up to the standards of all the regulatory agencies, including US FDA, MHRA, TGA and ANVISA Brazil. Backward integration through in-house API development and front-end efficient marketing/distribution of products would provide the desired impetus to the generics program from lab scale development to commercialization. |  |
|
| Alkem has committed a substantial amount of its resources to the development of Novel Drug Delivery Systems and this shall be the key element in providing momentum to consolidate its objective of value addition. |
|
| Alkem has an aspiration to make pioneer within the area of drug discovery, sometime in the recent future, and is looking into various models and therapeutic segments to carve out a meaningful space in the arena of medical needs that are not fulfilled. Alkem has in-licensed a number of novel products for the domestic market, form overseas collaborators, and continue to do so to provide the most advanced therapy avenues to the Indian patients. |
|
| Alkem is also collaborating with several Indian Universities and Indian companies for their development of difficult-to-make products and the development of other unique technologies. Alkem is progressing with leaps and bounds in the Nutraceutical segment of healthcare and wellness. Nutraceutical R & D efforts are mainly directed towards providing low fat and low calorie nutritional products for the better management of health. Commendable success has been achieved in this area of research and development. Alkem is building its future upon appropriate and timely protection of its R & D efforts. A number of patent applications are emerging from the in-house innovations which have gone on to be filed. |
|
| Alkem has state of the art manufacturing facility located at Taloja, Mumbai to carry out most advance research. Research at Alkem is guided a seasoned top team supported by over 200 scientist working on challenging assignments. Alkem - R&D has inherent strength in analytical chemistry and specialization in creating high quality formulations as per the required specifications. |
|
 |
|
|
| Special highlights are : |
- Formulation development for domestic market
- Formulation development for US / EU / AUS / Canada & Brazil markets
- Process development group for APIs and nutraceuticals
- Well equipped modern labs
- Pilot plants to manufacture regulatory batches
- Sophisticated information services
|
|
|
|
 |
|
| Alkem has MHRA approval of its parenteral cephalosporins, oral cephalosporins and general category products. Alkem's Group Company has TGA approval for its soft gelatin capsules facility. Alkem has also built a segregated facility for manufacturing immunosuppressant drugs and plans to create further facilities for other niche segments like lyophilized injectables, premixed ready to use Parenterals, steroid and oncology portfolios. This initiative would make Alkem a formidable India based manufacturing house. Backed by its internal R & D competence and track record, Alkem would go on to have a sustainable presence in a variety of dosage form segments across the markets of the globe. |
|
 |
|
